Clinical Trial Update: Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating obatoclax mesylate in combination with vincristine, doxorubicin, and dexrazoxane in pediatric patients with relapsed or refractory soli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Dexrazoxane hydrochloride (Dexrazoxane)
• Obatoclax Mesylate (obatoclax mesylate)
• Vincristine sulfate (VINCRISTINE SULFATE)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Status: TERMINATED